EP07.01-019 Multiinstitutional Patterns of Use and Compliance with Tumor Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma

Abstract

Given the significant lack of effective therapies for malignant pleural mesothelioma (MPM), Tumor Treating Fields (TTFields) was made available for use under an FDA-approved Humanitarian Device Exemption (HDE) protocol in 2019. In the phase 2 STELLAR study, a 68% median device usage rate (16.3 hours/day) was reported for MPM patients treated with TTFields along with platinum-based chemotherapy in the first 3 months. However, there is no reported real-world usage rate of TTFields for unresectable MPM to date and patterns of use may differ in clinical practice.